Analysis of circulating microRNAs in adrenocortical tumors

Laboratory Investigation

Volumn 94, Issue 3, 2014, Pages 331-339

  Szabó, Diana Rita ^a   Luconi, Michaela ^b   Szabó, Peter M ^c   Tóth, Miklós ^a   Szücs, Nikolette ^a   Horányi, János ^a   Nagy, Zoltán ^a   Mannelli, Massimo ^b   Patócs, Attila ^c   Rácz, Károly ^a   Igaz, Peter ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

adenoma; adrenocortical; biomarker; carcinoma; circulating; microRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 100; MICRORNA 1281; MICRORNA 16; MICRORNA 181B; MICRORNA 184; MICRORNA 192; MICRORNA 197; MICRORNA 210; MICRORNA 212; MICRORNA 24; MICRORNA 34 B; MICRORNA 455 3 P; MICRORNA 483 5 P; MICRORNA 548 A 3 P; MICRORNA 647; MICRORNA 885 5 P; MICRORNA 923; UNCLASSIFIED DRUG;

ADRENAL CORTEX TUMOR; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84896864495     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.148     Document Type: Article

References (53)

1. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002;87:5367-5384.
2. Aron D, Terzolo M, Cawood TJ. Adrenal incidentalomas. Best Pract Res Clin Endocrinol Metab 2012;26:69-82.
3. Fassnacht M, Libe R, Kroiss M, et al. Adrenocortical carcinoma: A clinician's update. Nat Rev Endocrinol 2011;7:323-335.
4. Lehmann T, Wrzesinski T. The molecular basis of adrenocortical cancer. Cancer Genet 2012;205:131-137.
5. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: Pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28.
6. Stigliano A, Cerquetti L, Sampaoli C, et al. Current and emerging therapeutic options in adrenocortical cancer treatment. J Oncol 2012;2012:408131.
7. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification. Cancer 2009;115:243-250.
8. Morelli V, Palmieri S, Salcuni AS, et al. Bilateral and unilateral adrenal incidentalomas: Biochemical and clinical characteristics. Eur J Endocrinol 2013;168:235-241.
9. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011;164:851-870.
10. Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011;96:3775-3784.
11. Patalano A, Brancato V, Mantero F. Adrenocortical cancer treatment. Hormone Res 2009;71(Suppl 1):99-104.
12. Zen K, Zhang CY. Circulating MicroRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2010;32:326-348.
13. Ozata DM, Caramuta S, Velazquez-Fernandez D, et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011;18:643-655.
14. Patterson EE, Holloway AK, Weng J, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483as a marker of malignancy. Cancer 2011;117:1630-1639.
15. Schmitz KJ, Helwig J, Bertram S, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 2011;64:529-535.
16. Soon PS, Tacon LJ, Gill AJ, et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009;15:7684-7692.
17. Tombol Z, Szabo PM, Molnar V, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: MicroRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 2009;16:895-906.
18. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids-The mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-477.
19. Velu VK, Ramesh R, Srinivasan AR. Circulating MicroRNAs as biomarkers in health and disease. J Clin Diagn Res 2012;6:1791-1795.
20. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012;72: 1443-1452.
21. Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013;132: 1602-1612.
22. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-10518.
23. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:355-360.
24. Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013;139:223-229.
25. Kroh EM, Parkin RK, Mitchell PS, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301.
26. McDonald JS, Milosevic D, Reddi HV, et al. Analysis of circulating microRNA: Preanalytical and analytical challenges. Clin Chem 2011;57:833-840.
27. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39:7223-7233.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
29. Brase JC, Wuttig D, Kuner R, et al. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010;9:306.
30. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011;80:193-208.
31. Kang K, Peng X, Luo J, et al. Identification of circulating miRNA biomarkers based on global quantitative real-Time PCR profiling. J Anim Sci Biotechnol 2012;3:4.
32. Chabre O, Libe R, Assie G, et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer 2013;20:579-594.
33. Steudemann C, Bauersachs S, Weber K, et al. Detection and comparison of microRNA expression in the serum of Doberman Pinschers with dilated cardiomyopathy and healthy controls. BMC Vet Res 2013;9:12.
34. Li C, Li JF, Cai Q, et al. MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol 2012;108:89-92.
35. Zheng XH, Cui C, Zhou XX, et al. Centrifugation: An important preanalytic factor that influences plasma microRNA quantification during blood processing. Chin J Cancer 2013;32:667-672.
36. Doghman M, El Wakil A, Cardinaud B, et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010;70:4666-4675.
37. Iliopoulos D, Bimpaki EI, Nesterova M, et al. MicroRNA signature of primary pigmented nodular adrenocortical disease: Clinical correlations and regulation of Wnt signaling. Cancer Res 2009;69:3278-3282.
38. Nurul-Syakima AM, Yoke-Kqueen C, Sabariah AR, et al. Differential microRNA expression and identification of putative miRNA targets and pathways in head and neck cancers. Int J Mol Med 2011;28: 327-336.
39. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-436.
40. Slaby O, Lakomy R, Fadrus P, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010;57:264-269.
41. Zhu W, Shan X, Wang T, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010;127:2520-2529.
42. Wang B, Hsu SH, Majumder S, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010;29:1787-1797.
43. Shi ZM, Wang XF, Qian X, et al. MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. RNA (New York, NY) 2013;19:552-560.
44. Wong TS, Liu XB, Wong BY, et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008;14:2588-2592.
45. Malzkorn B, Wolter M, Liesenberg F, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (Zurich, Switzerland) 2010;20:539-550.
46. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005;353:1768-1771.
47. Foley NH, Bray IM, Tivnan A, et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 2010;9:83.
48. Fassnacht M, Weismann D, Ebert S, et al. AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors. J Clin Endocrinol Metab 2005;90:4366-4370.
49. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008;14:1340-1348.
50. Puissegur MP, Mazure NM, Bertero T, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 2011;18:465-478.
51. Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010;126:73-80.
52. Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009;35:856-867.
53. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003;162:521-531.